Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study

被引：0
|
作者：
Giovannoni, G.
Cook, S.
Greenberg, S.
Chang, P.
Comi, G.
Rieckmann, P.
Sorensen, P. Soelberg
Vermersch, P.
机构：
来源：
JOURNAL OF NEUROLOGY | 2008年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P829
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [1] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
    Rieckmann, Peter
    Giovannoi, Gavin
    Cook, Stuart D.
    Greenberg, S.
    Chang, Peter
    Comi, Giancarlo
    Sorensen, Per Soelberg
    Vermersch, Patrick
    MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
  • [2] The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Beelke, M.
    Rieckmann, P.
    Sorensen, P. S.
    Vermersch, P.
    MULTIPLE SCLEROSIS, 2007, 13 : S245 - S245
  • [3] The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY)
    Giovannoni, G.
    Cook, S.
    Rieckmann, P.
    Vermersch, P.
    Soelberg-Sorensen, P.
    Comi, G.
    Chang, P.
    Lopez-Bresnahan, M.
    Kim, R.
    JOURNAL OF NEUROLOGY, 2006, 253 : 99 - 99
  • [4] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [5] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [6] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [7] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [8] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [9] Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Hamlett, Anthony
    Scaramozza, Matthew
    Lachenal, Nathalie
    NEUROLOGY, 2013, 80
  • [10] Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
    Rammohan, Kottil
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony
    Kurukulasuriya, Nuwan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2012, 1 (01) : 49 - 54
12345